Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Log out
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Commentary

Neonatal Jaundice and Kernicterus

AAP Subcommittee on Neonatal Hyperbilirubinemia
Pediatrics September 2001, 108 (3) 763-765; DOI: https://doi.org/10.1542/peds.108.3.763
1From the American Academy of Pediatrics, Subcommittee on Neonatal Hyperbilirubinemia.
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading
  • Abbreviations:
    AAP =
    American Academy of Pediatrics •
    G-6-PD =
    glucose-6-phosphate dehydrogenase
  • OBJECTIVE

    The American Academy of Pediatrics (AAP) Subcommittee on Hyperbilirubinemia is currently revising the practice parameter (guidelines) on neonatal hyperbilirubinemia published in October 1994.1 Although this revision is in progress, the Subcommittee wishes to bring the issue of kernicterus to the attention of the pediatric community and provide additional information pending a more formal assessment of the literature and an analysis of the risks and benefits of new approaches to the jaundiced infant. The Joint Commission on Accreditation of Healthcare Organizations has already issued an alert on this subject.2

    BACKGROUND

    Kernicterus, or bilirubin encephalopathy, is a condition caused by bilirubin toxicity to the basal ganglia and various brainstem nuclei. In the acute phase, severely jaundiced infants become lethargic, hypotonic and suck poorly. If the hyperbilirubinemia is not treated, the infant becomes hypertonic and may develop a fever and a high-pitched cry. The hypertonia is manifested by backward arching of the neck (retrocollis) and trunk (opisthotonus). Surviving infants usually develop a severe form of athetoid cerebral palsy, hearing loss, dental dysplasia, paralysis of upward gaze and, less often, intellectual and other handicaps.

    Kernicterus is a condition that is unfamiliar to most pediatricians practicing today. In the 1940s and 1950s, kernicterus was a common complication of hyperbilirubinemia associated with Rh erythroblastosis fetalis and, occasionally, ABO hemolytic disease. With the introduction of exchange transfusion, kernicterus became much less common. The use of Rh immunoglobulin all but eliminated erythroblastosis fetalis and phototherapy drastically reduced the need for exchange transfusion. In the last several years, however, there have been reports of kernicterus associated with extremely high serum bilirubin levels.3–9Most of these infants did not have obvious hemolytic disease or another recognized cause of neonatal jaundice. Many appeared to be otherwise healthy, breastfeeding newborns although frequently they were not receiving adequate nutrition and hydration. A significant proportion were <38 weeks' gestation (near-term infants).7

    RISK FACTORS FOR SEVERE HYPERBILIRUBINEMIA

    A comprehensive list of risk factors for severe hyperbilirubinemia can be found in a recent review.10 The common clinical risk factors identified in epidemiologic studies11 are listed in Table 1 in approximate order of importance. Additional risk factors can be identified by laboratory or bedside measurement.12 ,13 They include Rh and ABO incompatibility, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and an elevated hour-specific serum or transcutaneous bilirubin level.12 ,13 Rh disease is now rare and the blood type and Rh sensitization status of the mother is usually known at the time of a delivery, but many hospitals are no longer performing routine blood typing in infants of group O mothers so that the ABO status of the infant is often unknown. G-6-PD deficiency occurs in 11% to 13% of blacks14 and is more common among immigrants from the Mediterranean countries and Southeast Asia. It has been associated with cases of kernicterus in the United States.3 ,6 ,7 However, screening for G-6-PD deficiency is not performed routinely, in most hospitals the turnaround time for laboratory testing is 2 to 3 days, and appropriate evaluation for infants with abnormal levels is not well-defined.

    View this table:
    • View inline
    • View popup
    Table 1.

    Common Clinical Risk Factors for Severe Hyperbilirubinemia*

    ROOT CAUSES OF IDENTIFIED CASES OF KERNICTERUS

    Individual members of the committee have undertaken detailed review of published and unpublished cases of kernicterus; these reviews have used the framework of root cause analysis to identify likely fundamental underlying contributors to these cases.15 This analysis has identified the following potentially correctable causes for kernicterus:

    1. Early discharge (<48 hours) with no early follow-up (within 48 hours of discharge). This problem is particularly important in near-term infants (35–37 weeks' gestation).

    2. Failure to check the bilirubin level in an infant noted to be jaundiced in the first 24 hours.

    3. Failure to recognize the presence of risk factors for hyperbilirubinemia.

    4. Underestimating the severity of jaundice by clinical (ie, visual) assessment.

    5. Lack of concern regarding the presence of jaundice.

    6. Delay in measuring serum bilirubin level despite marked jaundice or in initiating phototherapy in the presence of elevated bilirubin levels.

    7. Failure to respond to parental concern regarding jaundice, poor feeding, or lethargy.

    CHANGES IN NEWBORN CARE

    Over the past decade, the most striking change in newborn practice has been the shortening of hospital stays.16 Shortened length of stay can affect the risk of severe jaundice in 2 ways. First, discharge at 48 hours or less means that in breastfeeding mothers the milk has not yet come in. These infants are therefore at risk for receiving inadequate fluid and nutrition, particularly if they are <38 weeks' gestation. Inadequate intake and hepatic immaturity together also place these infants at much greater risk for developing hyperbilirubinemia.11 In addition, short hospital stays mean that in almost all infants the peak bilirubin level will not occur until after discharge. Taken together, these changes mean that the management of neonatal jaundice is primarily an outpatient problem and that particular attention must be paid to breastfeeding infants and to infants who are <38 weeks' gestation.

    CURRENT AAP GUIDELINES

    The current AAP practice guidelines outline an approach to the management of the jaundiced newborn.1 All pediatricians should be familiar with the existing guidelines of the AAP, also available on the AAP's Web site at www.aap.org/policy/hyperb.htm. Although these guidelines cannot be applied to all cases, clinicians should document their management strategies including any significant deviation from the guidelines and the rationale for the course of action taken.

    The current guidelines address only healthy infants ≥37 weeks' gestation who do not have hemolytic disease. Preterm and sick infants and infants with hemolysis require much closer follow-up and more aggressive therapy. In otherwise healthy full-term and near-term newborn infants, kernicterus occurs only in the presence of severe hyperbilirubinemia. Thus, appropriate surveillance of newborns should identify those in need of phototherapy and, if necessary, exchange transfusion. If the current AAP guidelines for surveillance and treatment are followed, most cases of kernicterus should be prevented. This surveillance requires assessment in the nursery, early follow-up, and outpatient monitoring.

    RECOMMENDATIONS

    Current AAP Guidelines

    Recommendations from the current guidelines that deserve emphasis include the following:

    1. Any infant who is jaundiced before 24 hours requires a measurement of the serum bilirubin level and, if it is elevated,12 the infant should be evaluated for possible hemolytic disease.1

    2. Follow-up should be provided within 2 to 3 days of discharge to all neonates discharged at <48 hours after birth. Early follow-up is particularly important for infants <38 weeks' gestation. The timing of follow-up depends on the age of discharge and the presence of risk factors.11 In some cases, follow-up within 24 hours is necessary.

    Risk Assessment

    If early follow-up as currently recommended is uncertain or impossible, a decision regarding the timing of discharge or other follow-up should be based on risk assessment. There are now well-documented clinical and laboratory strategies for identifying newborns at risk for developing severe hyperbilirubinemia.11 ,12 ,13 ,16 They include the use of common clinical risk factors (Table 1) and the calculation of a risk index for predicting hyperbilirubinemia.11 An alternative strategy involves measurement of a serum or transcutaneous bilirubin level before discharge,12 ,13 ,16 which places an infant in a low, intermediate, or high-risk category for the subsequent development of hyperbilirubinemia. The timing of follow-up and the need for additional bilirubin levels will depend on the infant's age and the assessed risk.

    Breastfeeding Support

    Active support and advice to breastfeeding mothers should be provided both in the hospital and after discharge to ensure adequacy of intake for breastfed newborns.

    Information for Parents

    Pediatricians should convey a balanced approach when communicating with parents about jaundice. Most infants will become jaundiced and in the overwhelming majority of these infants, jaundice is entirely benign. A small fraction of these infants is at risk for developing extreme hyperbilirubinemia and kernicterus. As with other conditions in pediatrics (such as fever in the young infant), monitoring and surveillance of many infants are necessary to prevent a few infants from coming to harm. As with febrile infants, risk assessment strategies are needed to reliably identify almost all infants who are at serious risk of harm, while minimizing the burden and potential labeling of infants who are well.

    AREAS REQUIRING ADDITIONAL RESEARCH

    Incidence of Kernicterus and Outcomes

    Neonatal jaundice is very common but kernicterus is rare. Thus it is regrettable that no data exist on the incidence and prevalence of kernicterus in the US population. Such data are necessary to quantify the risks, benefits, and costs of various strategies aimed at preventing kernicterus.

    Additional research is also needed on the relationship of known risk factors to the development of kernicterus as well as more subtle developmental sequelae that have been associated with hyperbilirubinemia. These risk factors include the serum bilirubin level, duration of hyperbilirubinemia, the binding of bilirubin to albumin, gestational age, hemolysis, sepsis, acidosis, and other factors affecting the entry of bilirubin into the brain as well as the susceptibility of the neurons themselves to bilirubin toxicity.10 Evaluation of the effect of treatment on these risk factors and outcomes is also needed.

    Predicting Hyperbilirubinemia

    Measurement of a serum or transcutaneous bilirubin level on every infant before discharge has been recommended as a standard screening procedure to identify the level of risk for severe hyperbilirubinemia and the need for follow-up bilirubin levels.12 ,13Measurement of end-tidal carbon monoxide levels, an index of bilirubin production, can provide information about the presence or absence of hemolysis.17 Additional research is needed to quantify the risks, benefits, and costs of these and other strategies to prevent kernicterus. Until such information is available, the 1994 practice guidelines represent a good approach for most infants.

    CONCLUSION

    Recent reports of kernicterus indicate that this condition, although rare, is still occurring, yet most cases are preventable. This commentary emphasizes the importance of universal and close follow-up, responsiveness to parental concerns, and awareness of the real risk of extreme hyperbilirubinemia and kernicterus. In addition, particular attention should be paid to breastfeeding infants and to near-term infants who are at significant risk for severe hyperbilirubinemia.

    AAP Subcommittee on Neonatal Hyperbilirubinemia

    M. Jeffrey Maisels, MB, BCh, Chairperson

    Richard D. Baltz, MD

    Vinod K. Bhutani, MD

    Thomas B. Newman, MD, MPH

    Warren Rosenfeld, MD

    David K. Stevenson, MD

    Howard B. Weinblatt, MD

    Consultant

    Charles J. Homer, MD, MPH

    Chairperson, AAP Committee on Quality Improvement

    Staff

    Carla Herrerias

    Footnotes

      • Received June 5, 2001.
      • Accepted June 5, 2001.
    • Reprint requests to (M.J.M.) Department of Pediatrics, William Beaumont Hospital, 3601 W Thirteen Mile Rd, Royal Oak, MI 48073-6769. E-mail: jmaisels{at}beaumont.edu

    REFERENCES

    1. ↵
      1. American Academy of Pediatrics, Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia
      (1994) Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics 94:558–562.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Joint Commission on Accreditation of Healthcare Organizations.Sentinel Event Alert. Oak Brook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2001
    3. ↵
      1. Penn AA,
      2. Enzmann DR,
      3. Hahn JS,
      4. Stevenson DK
      (1994) Kernicterus in a full term infant. Pediatrics 93:1003–1006.
      OpenUrlAbstract/FREE Full Text
    4. ↵
      1. MacDonald M
      (1995) Hidden risks: early discharge and bilirubin toxicity due to glucose-6-phosphate dehydrogenase deficiency. Pediatrics 96:734–738.
      OpenUrlAbstract/FREE Full Text
    5. ↵
      1. Maisels MJ,
      2. Newman TB
      (1995) Kernicterus in otherwise healthy, breast-fed term newborns. Pediatrics 96:730–733.
      OpenUrlAbstract/FREE Full Text
    6. ↵
      1. Washington EC,
      2. Ector W,
      3. Abboud M,
      4. et al.
      (1995) Hemolytic jaundice due to G6PD deficiency causing kernicterus in a female newborn. South Med J 88:776–779.
      OpenUrlCrossRefPubMed
    7. ↵
      1. Johnson L,
      2. Brown AK
      (1999) A pilot registry for acute and chronic kernicterus in term and near-term infants. Pediatrics. 104:736.
      OpenUrl
    8. ↵
      1. Ebbesen F
      (2000) Recurrence of kernicterus in term and near-term infants in Denmark. Acta Paediatr 89:1–5.
      OpenUrlPubMed
    9. ↵
      1. Harris MC,
      2. Bernbaum JC,
      3. Polin JR,
      4. Zimmerman R,
      5. Polin RA
      (2001) Developmental follow-up of breast-fed term and near-term infants with marked hyperbilirubinemia. Pediatrics 107:1075–1080.
      OpenUrlAbstract/FREE Full Text
    10. ↵
      1. Dennery PA,
      2. Seidman DS,
      3. Stevenson DK
      (2001) Neonatal hyperbilirubinemia. . N Engl J Med 344:581–590.
      OpenUrlCrossRefPubMed
    11. ↵
      1. Newman TB,
      2. et al.
      (2000) Prediction and prevention of extreme hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med 154:1140–1147.
      OpenUrlCrossRefPubMed
    12. ↵
      1. Bhutani VK,
      2. Johnson L,
      3. Sivieri EM
      (1999) Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant bilirubinemia in healthy term and near-term newborns. Pediatrics 103:6–14.
      OpenUrlAbstract/FREE Full Text
    13. ↵
      Bhutani VK, Crossley GR, Adler S, et al. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn to assess the risk of severe hyperbilirubinemia. Pediatrics. 2000;106(2). Available at:http://www.pediatrics.org/cgi/content/full/106/2/e17
    14. ↵
      1. Kaplan M,
      2. Hammerman C
      (2000) Glucose-6-phosphate dehydrogenase-deficient neonates. A potential cause for concern in North America. Pediatrics 106:1478–1480.
      OpenUrlFREE Full Text
    15. ↵
      Joint Commission on Accreditation of Healthcare Organizations. Sentinel Event Policy and Procedures. Oak Brook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; Available at:www.jcaho.org
    16. ↵
      1. Eaton AP
      (2001) Early postpartum discharge: recommendations from a preliminary report to Congress. Pediatrics 107:400–404.
      OpenUrlFREE Full Text
    17. ↵
      1. Stevenson DK,
      2. Fanaroff AA,
      3. Maisels MJ,
      4. et al.
      (2001) Prediction of hyperbilirubinemia in near-term and term infants. Pediatrics. 108:31–39.
      OpenUrlAbstract/FREE Full Text
    • Copyright © 2001 American Academy of Pediatrics
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 108, Issue 3
    1 Sep 2001
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Neonatal Jaundice and Kernicterus
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Neonatal Jaundice and Kernicterus
    AAP Subcommittee on Neonatal Hyperbilirubinemia
    Pediatrics Sep 2001, 108 (3) 763-765; DOI: 10.1542/peds.108.3.763

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Neonatal Jaundice and Kernicterus
    AAP Subcommittee on Neonatal Hyperbilirubinemia
    Pediatrics Sep 2001, 108 (3) 763-765; DOI: 10.1542/peds.108.3.763
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • OBJECTIVE
      • BACKGROUND
      • RISK FACTORS FOR SEVERE HYPERBILIRUBINEMIA
      • ROOT CAUSES OF IDENTIFIED CASES OF KERNICTERUS
      • CHANGES IN NEWBORN CARE
      • CURRENT AAP GUIDELINES
      • RECOMMENDATIONS
      • AREAS REQUIRING ADDITIONAL RESEARCH
      • CONCLUSION
      • Footnotes
      • REFERENCES
    • Figures & Data
    • Info & Metrics
    • Comments

    Related Articles

    • No related articles found.
    • PubMed
    • Google Scholar

    Cited By...

    • Galactosaemia: an unusual cause of chronic bilirubin encephalopathy
    • A Quality Project to Improve Compliance With AAP Guidelines for Inpatient Management of Neonatal Hyperbilirubinemia
    • Evidence Suggests There Was Not a "Resurgence" of Kernicterus in the 1990s
    • Complex Multifactorial Nature of Significant Hyperbilirubinemia in Neonates
    • Universal Bilirubin Screening, Guidelines, and Evidence
    • Delayed Pediatric Office Follow-up of Newborns After Birth Hospitalization
    • Kernicterus in Preterm Infants
    • Impact of Postpartum Hospital-Stay Legislation on Newborn Length of Stay, Readmission, and Mortality in California
    • American Academy of Pediatrics guidelines for detecting neonatal hyperbilirubinaemia and preventing kernicterus
    • A Controlled, Randomized, Double-Blind Trial of Prophylaxis Against Jaundice Among Breastfed Newborns
    • Vigintiphobia Revisited
    • Neonatal bilirubin production-conjugation imbalance: effect of glucose-6-phosphate dehydrogenase deficiency and borderline prematurity
    • Levels of Neonatal Care
    • Cost-Effectiveness of Strategies That Are Intended to Prevent Kernicterus in Newborn Infants
    • Hyperbilirubinemia Guidelines and Unintended Harms: In Reply
    • Hyperbilirubinemia Benchmarking
    • Evaluation of a New Transcutaneous Bilirubinometer
    • Hospital Stay for Healthy Term Newborns
    • Incidence, Course, and Prediction of Hyperbilirubinemia in Near-Term and Term Newborns
    • Urgent Clinical Need for Accurate and Precise Bilirubin Measurements in the United States to Prevent Kernicterus
    • Corrected End-Tidal Carbon Monoxide Closely Correlates With the Corrected Reticulocyte Count in Coombs' Test-Positive Term Neonates
    • Management of Hyperbilirubinemia in Newborns: Measuring Performance by Using a Benchmarking Model
    • Applying the "10 Simple Rules" of the Institute of Medicine to Management of Hyperbilirubinemia in Newborns
    • Infants With Bilirubin Levels of 30 mg/dL or More in a Large Managed Care Organization
    • Induction of bilirubin clearance by the constitutive androstane receptor (CAR)
    • Bilirubin Genetics for the Nongeneticist: Hereditary Defects of Neonatal Bilirubin Conjugation
    • Kernicterus: Lessons for the Future From a Current Tragedy
    • Google Scholar

    More in this TOC Section

    • Artificial Intelligence for ROP Screening and to Assess Quality of Care: Progress and Challenges
    • Children’s Hospitals: We Get What We Pay For
    • Breastfeeding: A Key Investment in Human Capital
    Show more Commentary

    Similar Articles

    Subjects

    • Fetus/Newborn Infant
      • Fetus/Newborn Infant
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics